Birdwatch Note
2024-04-17 12:37:07 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
実際にはイベルメクチンのCOVID-19患者への使用は日本の2つのランダム化比較試験(RCT)でも https://www.kowa.co.jp/news/2022/press20220926.html https://www.kitasato-u.ac.jp/khp/topics/2022/20220930.html RCTのメタ解析でも臨床アウトカムの改善への有効性は見だされていません https://academic.oup.com/cid/article/74/6/1022/6310839?login=false https://journals.lww.com/aptm/Fulltext/2023/16010/Efficacy_and_safety_of_ivermectin_in_patients_with.2.aspx 日本だけの話ではなく、WHOも昨年11月でも新型コロナ治療のガイドラインで明示的に軽症治療でこの薬を使用しないよう推奨し、重症へは臨床試験においてのみ使用するよう推奨しています。 以下のページの最後の文章です https://www.who.int/news/item/10-11-2023-who-updates-guidelines-on-treatments-for-covid-19
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1780544129627541532
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1780576223825105066
- noteId - 1780576223825105066
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1713357427924
- tweetId - 1780544129627541532
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 実際にはイベルメクチンのCOVID-19患者への使用は日本の2つのランダム化比較試験(RCT)でも https://www.kowa.co.jp/news/2022/press20220926.html https://www.kitasato-u.ac.jp/khp/topics/2022/20220930.html RCTのメタ解析でも臨床アウトカムの改善への有効性は見だされていません https://academic.oup.com/cid/article/74/6/1022/6310839?login=false https://journals.lww.com/aptm/Fulltext/2023/16010/Efficacy_and_safety_of_ivermectin_in_patients_with.2.aspx 日本だけの話ではなく、WHOも昨年11月でも新型コロナ治療のガイドラインで明示的に軽症治療でこの薬を使用しないよう推奨し、重症へは臨床試験においてのみ使用するよう推奨しています。 以下のページの最後の文章です https://www.who.int/news/item/10-11-2023-who-updates-guidelines-on-treatments-for-covid-19
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2024-04-17 12:37:07 UTC (1713357427924) |
2024-04-17 19:13:55 UTC (1713381235419) |
CURRENTLY_RATED_HELPFUL | 2024-04-18 01:52:12 UTC (1713405132780) |
CURRENTLY_RATED_HELPFUL | 2024-04-17 19:13:55 UTC (1713381235419) |
CURRENTLY_RATED_HELPFUL |
Note Ratings
| rated at | rated by | |
| 2024-04-17 19:29:21 -0500 | Rating Details | |
| 2024-04-17 14:09:11 -0500 | Rating Details | |
| 2024-04-17 11:29:28 -0500 | Rating Details | |
| 2024-04-17 11:28:01 -0500 | Rating Details | |
| 2024-04-17 10:53:27 -0500 | Rating Details | |
| 2024-04-17 10:47:26 -0500 | Rating Details | |
| 2024-04-17 10:21:50 -0500 | Rating Details | |
| 2024-04-17 10:10:58 -0500 | Rating Details | |
| 2024-04-17 10:05:03 -0500 | Rating Details | |
| 2024-04-17 09:38:22 -0500 | Rating Details | |
| 2024-04-17 09:25:06 -0500 | Rating Details | |
| 2024-04-17 09:22:50 -0500 | Rating Details | |
| 2024-04-17 09:16:11 -0500 | Rating Details | |
| 2024-04-17 08:44:44 -0500 | Rating Details | |
| 2024-04-17 08:40:13 -0500 | Rating Details | |
| 2024-04-17 08:22:35 -0500 | Rating Details | |
| 2024-04-17 08:22:09 -0500 | Rating Details | |
| 2024-04-17 08:10:36 -0500 | Rating Details | |
| 2024-04-17 08:09:03 -0500 | Rating Details | |
| 2024-04-17 08:08:38 -0500 | Rating Details | |
| 2024-04-17 08:07:40 -0500 | Rating Details | |
| 2024-04-17 08:06:18 -0500 | Rating Details | |
| 2024-04-17 08:03:08 -0500 | Rating Details | |
| 2024-04-17 08:01:28 -0500 | Rating Details | |
| 2024-04-17 08:00:07 -0500 | Rating Details | |
| 2024-04-17 08:00:07 -0500 | Rating Details | |
| 2024-04-17 08:00:01 -0500 | Rating Details | |
| 2024-04-17 07:59:18 -0500 | Rating Details | |
| 2024-04-17 07:57:42 -0500 | Rating Details | |
| 2024-04-17 07:56:59 -0500 | Rating Details | |
| 2024-04-17 07:53:50 -0500 | Rating Details | |
| 2024-04-17 07:49:42 -0500 | Rating Details | |
| 2024-04-17 07:39:45 -0500 | Rating Details | |
| 2024-04-18 09:34:35 -0500 | Rating Details | |
| 2024-04-17 22:06:31 -0500 | Rating Details | |
| 2024-04-17 21:51:07 -0500 | Rating Details | |
| 2024-04-17 21:25:37 -0500 | Rating Details | |
| 2024-04-17 21:22:51 -0500 | Rating Details | |
| 2024-04-17 20:56:12 -0500 | Rating Details | |
| 2024-04-17 20:54:16 -0500 | Rating Details | |
| 2024-04-17 20:45:24 -0500 | Rating Details | |
| 2024-04-18 06:02:20 -0500 | Rating Details | |
| 2024-04-18 05:53:18 -0500 | Rating Details | |
| 2024-04-18 05:26:22 -0500 | Rating Details | |
| 2024-04-18 02:33:36 -0500 | Rating Details | |
| 2024-04-18 01:38:47 -0500 | Rating Details | |
| 2024-04-18 00:56:25 -0500 | Rating Details | |
| 2024-04-18 00:51:30 -0500 | Rating Details | |
| 2024-04-18 00:45:12 -0500 | Rating Details | |
| 2024-04-17 22:53:18 -0500 | Rating Details | |
| 2024-04-17 21:59:44 -0500 | Rating Details | |
| 2024-04-17 21:47:07 -0500 | Rating Details | |
| 2024-04-17 21:38:49 -0500 | Rating Details | |
| 2024-04-17 21:33:46 -0500 | Rating Details | |
| 2024-04-17 21:27:14 -0500 | Rating Details | |
| 2024-04-17 21:09:57 -0500 | Rating Details | |
| 2024-04-17 20:54:09 -0500 | Rating Details | |
| 2024-04-17 20:48:08 -0500 | Rating Details | |
| 2024-04-17 20:47:59 -0500 | Rating Details | |
| 2024-04-17 20:43:14 -0500 | Rating Details | |
| 2024-04-17 20:42:34 -0500 | Rating Details | |
| 2024-04-17 20:42:14 -0500 | Rating Details | |
| 2024-04-17 20:37:14 -0500 | Rating Details | |
| 2024-04-17 20:32:55 -0500 | Rating Details | |
| 2024-04-17 15:05:50 -0500 | Rating Details | |
| 2024-04-17 14:42:13 -0500 | Rating Details | |
| 2024-04-17 11:09:11 -0500 | Rating Details | |
| 2024-04-17 10:00:42 -0500 | Rating Details | |
| 2024-04-17 09:41:11 -0500 | Rating Details | |
| 2024-04-17 09:35:38 -0500 | Rating Details | |
| 2024-04-17 09:25:44 -0500 | Rating Details | |
| 2024-04-17 09:10:22 -0500 | Rating Details | |
| 2024-04-17 08:53:12 -0500 | Rating Details | |
| 2024-04-17 08:18:21 -0500 | Rating Details | |
| 2024-04-17 08:05:56 -0500 | Rating Details | |
| 2024-04-17 08:05:49 -0500 | Rating Details | |
| 2024-04-17 08:03:30 -0500 | Rating Details | |
| 2024-04-17 07:59:09 -0500 | Rating Details | |
| 2024-04-17 07:54:40 -0500 | Rating Details | |
| 2024-04-17 07:52:08 -0500 | Rating Details | |
| 2024-04-17 07:48:12 -0500 | Rating Details | |
| 2024-04-19 23:17:18 -0500 | Rating Details | |
| 2024-04-19 20:49:35 -0500 | Rating Details | |
| 2024-04-18 07:07:42 -0500 | Rating Details | |
| 2024-04-24 03:19:28 -0500 | Rating Details | |
| 2024-04-20 08:20:43 -0500 | Rating Details | |
| 2024-04-20 07:59:04 -0500 | Rating Details | |
| 2024-04-19 23:06:56 -0500 | Rating Details | |
| 2024-04-19 20:56:03 -0500 | Rating Details | |
| 2024-04-17 22:22:13 -0500 | Rating Details | |
| 2024-04-21 21:35:27 -0500 | Rating Details | |
| 2024-04-20 17:22:41 -0500 | Rating Details | |
| 2024-04-20 08:36:34 -0500 | Rating Details | |
| 2024-04-18 12:33:01 -0500 | Rating Details | |
| 2024-04-18 04:26:03 -0500 | Rating Details | |
| 2024-04-18 04:05:08 -0500 | Rating Details | |
| 2024-04-18 00:46:38 -0500 | Rating Details | |
| 2024-04-17 23:20:39 -0500 | Rating Details | |
| 2024-04-17 22:30:38 -0500 | Rating Details | |
| 2024-04-17 22:27:01 -0500 | Rating Details | |
| 2024-04-17 21:54:15 -0500 | Rating Details | |
| 2024-04-17 21:37:38 -0500 | Rating Details | |
| 2024-04-17 21:20:38 -0500 | Rating Details | |
| 2024-04-17 21:12:41 -0500 | Rating Details | |
| 2024-04-17 21:03:50 -0500 | Rating Details | |
| 2024-04-17 20:46:35 -0500 | Rating Details | |
| 2024-04-17 20:45:11 -0500 | Rating Details | |
| 2024-04-17 20:44:11 -0500 | Rating Details | |
| 2024-04-17 20:42:43 -0500 | Rating Details | |
| 2024-04-17 20:33:06 -0500 | Rating Details | |
| 2024-04-17 16:52:28 -0500 | Rating Details | |
| 2024-04-17 13:30:04 -0500 | Rating Details | |
| 2024-04-17 12:13:04 -0500 | Rating Details | |
| 2024-04-17 11:58:06 -0500 | Rating Details | |
| 2024-04-17 10:06:48 -0500 | Rating Details | |
| 2024-04-17 09:37:03 -0500 | Rating Details | |
| 2024-04-17 08:52:09 -0500 | Rating Details | |
| 2024-04-17 08:49:39 -0500 | Rating Details | |
| 2024-04-17 08:47:58 -0500 | Rating Details | |
| 2024-04-17 08:46:00 -0500 | Rating Details | |
| 2024-04-17 08:44:49 -0500 | Rating Details | |
| 2024-04-17 08:37:38 -0500 | Rating Details | |
| 2024-04-17 08:25:22 -0500 | Rating Details | |
| 2024-04-17 08:22:20 -0500 | Rating Details | |
| 2024-04-17 08:19:28 -0500 | Rating Details | |
| 2024-04-17 08:17:01 -0500 | Rating Details | |
| 2024-04-17 08:07:28 -0500 | Rating Details | |
| 2024-04-17 08:07:11 -0500 | Rating Details | |
| 2024-04-17 08:04:36 -0500 | Rating Details | |
| 2024-04-17 07:59:43 -0500 | Rating Details | |
| 2024-04-17 07:58:45 -0500 | Rating Details | |
| 2024-04-17 07:52:33 -0500 | Rating Details | |
| 2024-04-17 07:49:52 -0500 | Rating Details | |
| 2024-04-17 07:46:34 -0500 | Rating Details | |
| 2024-04-17 07:46:21 -0500 | Rating Details | |
| 2024-04-18 02:43:49 -0500 | Rating Details | |
| 2024-04-18 00:20:26 -0500 | Rating Details | |
| 2024-04-17 20:32:18 -0500 | Rating Details | |
| 2024-04-17 22:12:33 -0500 | Rating Details | |
| 2024-05-05 19:02:56 -0500 | Rating Details | |
| 2024-04-18 03:16:21 -0500 | Rating Details |